TLRY
Tilray Brands, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$3.99
+1.27%Next report
Analyst consensus
- Next report date
- Oct 8, 2026
- EPS estimate
- -$0.17
- Revenue estimate
- $268.9M
Latest reported
- Last report date
- Jul 28, 2026
- EPS actual
- -$0.43
- EPS estimate
- -$0.01
- Revenue actual
- $281.7M
- Revenue estimate
- $246.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 10
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -909.3%
- Revenue beats (12Q)
- 6
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 28, 2026 | -$0.01 | -$0.43 | Miss -3471.43% | $281.7M |
| Apr 1, 2026 | -$0.14 | -$0.24 | Miss -71.43% | $206.7M |
| Jan 8, 2026 | -$0.14 | -$0.41 | Miss -192.86% | $303.9M |
| Oct 9, 2025 | -$0.27 | -$0.00 | Beat 98.43% | $287.8M |
| Apr 8, 2025 | -$0.04 | -$0.10 | Miss -150.00% | $185.8M |
| Jan 10, 2025 | -$0.04 | -$0.10 | Miss -150.00% | $211.0M |
| Oct 10, 2024 | -$0.04 | -$0.04 | Miss -11.11% | $200.0M |
| Apr 9, 2024 | -$0.05 | -$0.12 | Miss -140.00% | $188.3M |
| Jan 9, 2024 | -$0.06 | -$0.07 | Miss -11.63% | $193.5M |
| Oct 4, 2023 | -$0.05 | -$0.10 | Miss -100.00% | $176.8M |
| Jul 26, 2023 | -$0.05 | -$0.15 | Miss -200.00% | $183.8M |
| Apr 10, 2023 | -$0.05 | -$0.04 | Beat 20.00% | $145.5M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 8, 2026